|
|
 |
| |
|
Home > Drug Companies > Kos Pharmaceuticals, Inc.
| |
Pharmaceutical Courses |
|
Pharmacy Technician
Allied College
Arnold, MO |
Pharmacy Technician
Allied College
Saint Ann, MO |
Pharmacy Technician
Cambridge College
Portland, OR |
Pharmacy Technician
Cambridge College
Seattle, WA |
Pharmacy Technician
High Tech Institute
Irving, TX |
Pharmacy Technician
High Tech Institute
Atlanta, GA |
Pharmacy Technician
High Tech Institute
Memphis, TN |
Pharmacy Technician
High Tech Institute
Minneapolis, MN |
Pharmacy Technician
High Tech Institute
Orlando, FL |
Pharmacy Technician
High Tech Institute
Sacramento, CA |
Pharmacy Technician
The Bryman School
Phoenix, AZ |
|
Kos Pharmaceuticals, Inc.
Kos Pharmaceuticals named after the Greek island where Hippocrates founded the science of medicine is a fully integrated specialty pharmaceutical company engaged in the development of proprietary prescription pharmaceutical products, principally for treatment of cardiovascular, respiratory and metabolic diseases. The Company’s principal product development strategy is to reformulate existing pharmaceutical products with large market potential to improve safety, effectiveness and patient compliance.
The Company is concentrating on the cardiovascular and respiratory markets because of their extraordinary size and growth, because physician prescribing patterns in these markets are importantly influenced by an identifiable group of physicians that can be addressed by their relatively small specialty sales force, and because of management's extensive experience with these markets. They currently market two proprietary innovative drugs for the treatment of cholesterol disorders and one for asthma.
The Company was founded in 1988 by Michael Jaharis, one of the major shareholders and the principal architect of the very unique and extraordinarily successful Key. Though still a young company with a pioneering spirit, they are playing an increasingly important role in advancing the science of cholesterol management, from introducing the first FDA approved once daily form of niacin in Niaspan, to bringing to market Advisor, the first and only dual component therapy approved by the FDA for treating multiple lipid disorders.
The Company is proud of this record of discovery and innovation. Indeed, it is the platform on which they are determined to build a leading specialty pharmaceutical company focused on the treatment and prevention of chronic disease a company pioneering medicines for a better life.
Back to Drug Companies
|
|
|
|
|
|
|
|